Nonsteroidal Anti-Inflammatory Drugs Decrease Coagulopathy Incidence in Severe Burn Patients

Lyndon Huang; Kassandra Corona; Kendall Wermine; Elvia Villarreal; Giovanna De La Tejera; Phillip Howard Keys; Alen Palackic; Amina El Ayadi; George Golovko; Steven E Wolf; Juquan Song

doi:10.3390/ebj5020009

Nonsteroidal Anti-Inflammatory Drugs Decrease Coagulopathy Incidence in Severe Burn Patients

Eur Burn J. 2024 Apr 28;5(2):104-115. doi: 10.3390/ebj5020009.

Affiliations

¹ School of Medicine, University of Texas Medical Branch, Galveston, TX 77555, USA.
² Department of Hand, Plastic and Reconstructive Surgery, Burn Center, BG Trauma Center Ludwigshafen, University of Heidelberg, Ludwig-Guttmann-Str. 13, 67071 Ludwigshafen, Germany.
³ Department of Surgery, University of Texas Medical Branch, Galveston, TX 77555, USA.
⁴ Department of Pharmacology, University of Texas Medical Branch, Galveston, TX 77555, USA.

Abstract

The study investigated the impact of nonsteroidal anti-inflammatory drugs (NSAIDs) on burn-induced coagulopathy in severely burned patients. Patients with a greater than 20% TBSA were identified in the TriNetX research network and categorized into receiving or not receiving NSAIDs in the first week after the burn. The statistical significance of the rate of burn-induced coagulopathy, mortality and sepsis in the week following injury was analysed. We observed 837 severely burned patients taking NSAIDS during the week following the burn and 1036 patients without. After matching for age, gender and race, the risk of burn-induced coagulopathy significantly decreased (p < 0.0001) in patients taking NSAIDs (17.7%) compared to those without (32.3%). Patients taking NSAIDs were also less likely to develop sepsis (p < 0.01) and thrombocytopenia (p < 0.001) or die the week following injury (p < 0.0001). In conclusion, the early protective effects of NSAIDs at reducing the risk of coagulopathy as well as sepsis and mortality occur during the acute phase of burns.

Keywords: TriNetX database; international normalized ratio (INR); mortality; retrospective study; sepsis.

Grants and funding

This research was supported in part by a Clinical and Translational Science Award (UL1 TR001439) from the National Center for Advancing Translational Sciences.